Bio News

U.S.-based Mayo Clinic Laboratories has made a strategic investment in Pathology Asia Holdings and announced a collaboration.
Through its genomics subsidiary, LifeStrands Genomics, the two organizations will expand access to advanced molecular and genomic testing in Southeast Asia, Australia and New Zealand.
William Morice, CEO of Mayo Clinic Laboratories, has been appointed a scientific adviser to Pathology Asia Holdings.

Biobook Team
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia